Veracyte
VCYTVeracyte is a global diagnostics company specializing in high-performance molecular tests that provide clinicians with critical insights for cancer diagnosis and treatment.
Earnings
Next report
Nov 4, 2026 (In 2 days)Segments
Competitors
By market cap
By revenue growth
Profile
Veracyte is a global diagnostics company specializing in high-performance molecular tests that provide clinicians with critical insights for cancer diagnosis and treatment. The company leverages unique cancer biology to offer prognostic and predictive data, helping patients avoid unnecessary procedures and accelerating time to appropriate therapy. Their operations utilize a dual-model approach, combining centralized laboratory services in the United States with international distribution of diagnostic kits for local hospital use.
A leading provider of genomic tests for prostate and thyroid cancer with a growing presence in breast and bladder cancer diagnostics.
FAQ
- What is Veracyte's market cap?
- Veracyte (VCYT) has a market capitalization of $4.2B and trades on NASDAQ.
- What is Veracyte's revenue and profitability?
- Veracyte generated $561.9M in trailing twelve-month revenue with net income of $114.5M, representing a net margin of 20.4%. Gross margin stands at 71.7%, with free cash flow of $166.0M. The latest reported period is Q2 2026.
- Who are Veracyte's competitors?
- Veracyte's key competitors include Castle Biosciences, Personalis, Inc. Common Stock, Guardant Health, and others. These companies compete in similar markets and product categories.
- What subsidiaries does Veracyte have?
- Veracyte's subsidiaries include Decipher Biosciences.
- Where is Veracyte headquartered?
- Veracyte is headquartered in United States of America and employs approximately 815 people. It has been publicly traded since 2013.
